Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 6:
NRx Pharmaceuticals, Inc. NRXP: This bio-pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 46.2% over the last 60 days.
NRx Pharmaceuticals, Inc. Price and Consensus
NRx Pharmaceuticals, Inc. price-consensus-chart | NRx Pharmaceuticals, Inc. Quote
NRx Pharmaceuticals’ shares gained 79.3% over the last three months compared with the S&P 500’s advanced of 4.2%. The company possesses a Momentum Score of A.
NRx Pharmaceuticals, Inc. Price
NRx Pharmaceuticals, Inc. price | NRx Pharmaceuticals, Inc. Quote
Pro-Dex, Inc. PDEX: This medical device contract manufacturer company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 40.9% over the last 60 days.
Pro-Dex, Inc. Price and Consensus
Pro-Dex, Inc. price-consensus-chart | Pro-Dex, Inc. Quote
Pro-Dex’s shares gained 67.7% over the last three months compared with the S&P 500’s advanced of 4.2%. The company possesses a Momentum Score of A.
Pro-Dex, Inc. Price
Pro-Dex, Inc. price | Pro-Dex, Inc. Quote
Puma Biotechnology, Inc. PBYI: This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 24% over the last 60 days.
Puma Biotechnology, Inc. Price and Consensus
Puma Biotechnology, Inc. price-consensus-chart | Puma Biotechnology, Inc. Quote
Puma Biotechnology’s shares gained 10.9% over the last three months compared with the S&P 500’s advanced of 4.2%. The company possesses a Momentum Score of A.
Puma Biotechnology, Inc. Price
Puma Biotechnology, Inc. price | Puma Biotechnology, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Zacks’ Research Chief Names “Stock Most Likely to Double”
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report
Pro-Dex, Inc. (PDEX) : Free Stock Analysis Report
NRx Pharmaceuticals, Inc. (NRXP) : Free Stock Analysis Report